Drugs of interest to pathologists
Drugs related to clinical pathology
Ruxolitinib phosphate

Author: Him G. Kwee, M.D. (see Authors page)

Revised: 22 November 2017, last major update February 2012

Copyright: (c) 2002-2017, PathologyOutlines.com, Inc.

PubMed Search: Ruxolitinib review "loattrfree full text"[sb]

Cite this page: Kwee, H.G. Ruxolitinib phosphate. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/drugsjakafi.html. Accessed December 13th, 2017.
Definition / general
  • Janus kinase inhibitor
Trade name
  • Jakafi®
Clinical information
Approved by US Food and Drug Administration on November 16, 2011 for:
Molecular theory
  • Janus family of kinases consists of JAK1, JAK2, JAK3 and TYK2
  • Ruxolitinib inhibits JAK1 and JAK2, which mediate the signaling of cytokines and growth factors that are important for hematopoiesis and immune functions
  • JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization to the nucleus, leading to modulation of gene expression
  • Myelofibrosis is associated with dysregulated JAK1 and JAK2 signaling
  • JAK2 V617F mutation is found in most patients with BCR-ABL negative myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia and primary myelofibrosis (Leuk Lymphoma 2008;49:388), see also myelofibrosis topic and chronic myeloid neoplasms chapter
  • Ruxolitinib can cause significant improvement in myelofibrosis patients, specifically decrease in spleen size, fatigue, pruritus, night sweats and bone pain (Blood 2009;113:2895)